BMO Capital Upgrades Neurocrine Biosciences to Market Perform, Raises Price Target to $96
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst Evan Seigerman has upgraded Neurocrine Biosciences (NASDAQ:NBIX) from Underperform to Market Perform and raised the price target from $91 to $96.
July 06, 2023 | 9:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences has been upgraded to Market Perform by BMO Capital, with a raised price target of $96.
The upgrade from Underperform to Market Perform by BMO Capital indicates a more positive outlook for Neurocrine Biosciences. The raised price target from $91 to $96 suggests that the analyst believes the stock has potential for growth in the short term. This could lead to increased investor interest and potentially a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100